DGAP-News: BB BIOTECH AG / Key word(s): Miscellaneous
BB Biotech statement on MiFID II (news with additional features)
30.10.2017 / 17:40
The issuer is solely responsible for the content of this announcement.
Media Release of October 30, 2017
BB Biotech statement on MiFID II
Under the European Union's new Markets in Financial Instruments Directive MiFID II that enters into effect at the beginning of 2018, financial services providers will be required to provide clients with a transparent disclosure of research costs and state how those costs will be absorbed. Bellevue Asset Management, the company retained by BB Biotech, will absorb the costs incurred for research and will not pass them onto its shareholders.
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=WCDJYRBCMA Document title: Media release
30.10.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone:
+41 52 624 08 45
E-mail:
info@bbbiotech.com
Internet:
www.bbbiotech.ch
ISIN:
CH0038389992
WKN:
A0NFN3
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
BB BIOTECH AG 
